NewsBenzingaBarclays inicia cobertura de TransMedics Group con calificación de sobreponderar y anuncia un precio objetivo de 120 dólares. Barclays inicia cobertura de TransMedics Group con calificación de sobreponderar y anuncia un precio objetivo de 120 dólares. Benzinga 2026.10.07 13:19 (GMT+0) Open on Benzinga Other news 'Former Tesla Optimus Lead is Launching an Industrial Robot Startup'- The Information Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114 Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359 HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22 Morgan Stanley Maintains Equal-Weight on Alcoa, Lowers Price Target to $50 Google Prepares Antigravity For Gemini 4 Argon And Concierge
